A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients

Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors

(2016) M. Nauck   DIABETES OBESITY & METABOLISM

Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes

(2016) Uchenna Anyanwagu et al.   HEART

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics

(2015) Lisbeth V. Jacobsen et al.   CLINICAL PHARMACOKINETICS

Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical Trials

(2015) Jeanne S. Geiser et al.   CLINICAL PHARMACOKINETICS

Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial

(2015) Juris J. Meier et al.   DIABETES CARE

Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2)

(2015) Francesco Giorgino et al.   DIABETES CARE

Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study

(2015) E. Araki et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

(2015) T. Karagiannis et al.   DIABETES OBESITY & METABOLISM

One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial

(2015) S. C. L. Gough et al.   DIABETES OBESITY & METABOLISM

Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects

(2015) Reinhard H. A. Becker et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis

(2015) Xiaoyan Song et al.   Scientific Reports

Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro

(2014) Julio Rosenstock et al.   DIABETES CARE

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2014) Silvio E. Inzucchi et al.   DIABETES CARE

Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes

(2014) Michaela Diamant et al.   DIABETES CARE

A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON)

(2014) C. Mathieu et al.   DIABETES OBESITY & METABOLISM

Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes

(2014) D. D'Alessio et al.   DIABETES OBESITY & METABOLISM

Is insulin the most effective injectable antihyperglycaemic therapy?

(2014) J. B. Buse et al.   DIABETES OBESITY & METABOLISM

Risk of pancreatitis in patients treated with incretin-based therapies

(2014) Juris J. Meier et al.   DIABETOLOGIA

HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea

(2014) Peter N. Weissman et al.   DIABETOLOGIA

Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight

(2014) Laurie L. Baggio et al.   JOURNAL OF CLINICAL INVESTIGATION

Glucagon-like peptide 1 receptor agonist therapy is more efficacious than insulin glargine for poorly controlled type 2 diabetes: A systematic review and meta-analysis

(2014) Fu-peng Liu et al.   Journal of Diabetes

Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial

(2014) Michaela Diamant et al.   Lancet Diabetes & Endocrinology

Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes

(2014) Stephen C L Gough et al.   Lancet Diabetes & Endocrinology

Management of type 2 diabetes: NICE guidelines

(2013) L. Sibal et al.   CLINICAL MEDICINE

The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily: A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes

(2013) L. Meneghini et al.   DIABETES CARE

Baseline HbA1c predicts attainment of 7.0% HbA1c target with structured titration of insulin glargine in type 2 diabetes: a patient-level analysis of 12 studies

(2013) M. C. Riddle et al.   DIABETES OBESITY & METABOLISM

Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin

(2013) C. Kapitza et al.   DIABETES OBESITY & METABOLISM

Effects of the GLP-1 receptor agonist lixisenatide on postprandial glucose and gastric emptying – preclinical evidence

(2013) Ulrich Werner   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis

(2013) Louise E Robinson et al.   BMJ Open

Efficacy and Safety Profile of Exenatide Once Weekly Compared With Insulin Once Daily in Japanese Patients With Type 2 Diabetes Treated With Oral Antidiabetes Drug(s): Results From a 26-Week, Randomized, Open-Label, Parallel-Group, Multicenter, Noninferiority Study

(2012) Nobuya Inagaki et al.   CLINICAL THERAPEUTICS

Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir: Randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas

(2012) M. Davies et al.   DIABETES CARE

Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes: A 1-year, randomized, treat-to-target trial (BEGIN Once Long)

(2012) B. Zinman et al.   DIABETES CARE

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETES CARE

Effects of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight: A Meta-Analysis

(2012) Matteo Monami et al.   Experimental Diabetes Research

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study

(2012) John B Buse et al.   LANCET

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

(2012) Juris J. Meier   Nature Reviews Endocrinology

Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans

(2011) M. A. Nauck et al.   DIABETES

Exenatide Twice Daily Versus Premixed Insulin Aspart 70/30 in Metformin-Treated Patients With Type 2 Diabetes: A randomized 26-week study on glycemic control and hypoglycemia

(2011) B. Gallwitz et al.   DIABETES CARE

Effects of Exenatide on Measures of  -Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes

(2011) M. C. Bunck et al.   DIABETES CARE

Glucagon-like peptide-1 receptor agonists versus insulin in inadequately controlled patients with type 2 diabetes mellitus: a meta-analysis of clinical trials

(2011) Y. Wang et al.   DIABETES OBESITY & METABOLISM

Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies

(2011) Michael Elashoff et al.   GASTROENTEROLOGY

One-year treatment with exenatide vs. Insulin Glargine: Effects on postprandial glycemia, lipid profiles, and oxidative stress

(2010) Mathijs C. Bunck et al.   ATHEROSCLEROSIS

Glucagon-like peptide-1 receptor agonists versus insulin glargine for type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials

(2010) Wei-Xin Li et al.   CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

(2010) Michaela Diamant et al.   LANCET

Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea

(2009) Richard Bergenstal et al.   CURRENT MEDICAL RESEARCH AND OPINION

One-Year Treatment With Exenatide Improves  -Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients: A randomized, controlled trial

(2009) M. C. Bunck et al.   DIABETES CARE

Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study

(2009) M. J. Davies et al.   DIABETES OBESITY & METABOLISM

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

(2009) D. Russell-Jones et al.   DIABETOLOGIA

Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Albiglutide, a Long-Acting Glucagon-Like Peptide-1 Mimetic, in Patients with Type 2 Diabetes

(2008) Jessica E. Matthews et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

(2008) Daniel J Drucker et al.   LANCET